PHARMACOECONOMIC STUDY OF OLMESARTAN/LERCANIDIPINE AND OFENOPRIL/LERCANIDIPINE COMBINATIONS IN THE TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION
Abstract
Objective. Pharmacoeconomic analysis of the use of combinations of antihypertensive drugs were olmesartan/lercanidipine and zofenopril/lercanidipine in patients with essential hypertension II-III stage.
Materials and methods. The authors performed prospective randomized uncontrolled study. Were examined in 27 people essential hypertension with II-III stage age from 40 to 71 years before and after the use of combinations of drugs olmesartan/lercanidipine and zofenopril/lercanidipine. An ABC/VEN-analysis, сost-effectiveness analysis, comparative assessment of the incidence of side effects of the studied drugs were performed.
Results. Anti-hypertensive effect of the studied combinations of drugs were not significantly different and equally effectively reduced blood pressure. But the cost of blood pressure reduction at 1 mm Hg was the smallest in the group zofenopril/lercanidipine.
Conclusion. The results of pharmacoeconomic analysis to be more cost-effective combination for the treatment of patients with essential hypertension II-III stage is the combination of zofenopril/lercanidipine.
About the Authors
D. S. Kaskaeva
Krasnoyarsk State Medical University named after Professor V. F. Voino-Yasenetsky
Russian Federation
Russian Federation
PhD, head of the Department of General practice, associate Professor in the Department of outpatient therapy, family medicine and healthy lifestyle with a course of postgraduate education State budgetary educational institution of higher professional education “Krasnoyarsk state medical University named after Professor V. F. Voyno-Yasenetsky”. Address: ul. Partizana Zheleznyaka, 1, Krasnoyarsk, Russia, 660022
M. M. Petrova
Krasnoyarsk State Medical University named after Professor V. F. Voino-Yasenetsky
Russian Federation
Russian Federation
MD, Vice-rector on scientific work, head of the Department of polyclinic therapy and family medicine and healthy lifestyle with a course of postgraduate education State budgetary educational institution of higher professional education “Krasnoyarsk state medical University named after Professor V. F. Voyno-Yasenetsky”. Address: ul. Partizana Zheleznyaka, 1, Krasnoyarsk, Russia, 660022
O. V. Zimnitskaya
Krasnoyarsk State Medical University named after Professor V. F. Voino-Yasenetsky
Regional state budgetary healthcare institution Regional clinical hospital
Russian Federation
Russian Federation
postgraduate student of the Department of polyclinic therapy and family medicine and healthy lifestyle with a course of postgrad-uate education State budgetary educational institution of higher professional education “Krasnoyarsk state medical University named after Professor V. F. Voyno-Yasenetsky”; cardiologist Consultative-diagnostic clinic Regional clinical hospital
References
1. Begina O. A., Gladchuk N. V., Nazar’eva N. A. Pharmacoeconomic analysis of rationality of use of funds under the article “Medicine” for 2015 (ABC-VEN analysis). The collection of materials of 6-th international scientific-methodological conference “Formoobrazovanie-2016” [Farmakoekonomicheskii analiz ratsional’nosti ispol’zovaniya denezhnykh sredstv po stat’e «Medikamenty» za 2015 god (ABC-VEN analiz). Sbornik materialov 6-i mezhdunarodnoi nauchno-metodicheskoi konferentsii «Farmobrazovanie- 2016» (in Russian)]. Voronezh. 2016; 169-172.
2. Boriskin P. V., Supil’nikov A. A. Vestnik meditsinskogo instituta «REAVIZ». 2016; 2: 28-45.
3. Lilli L. Pathophysiology of the cardiovascular system. Ed Lilly. Per. from English. 3-e Izd., corrected and revised [Patofiziologiya serdechno-sosudistoi sistemy. Pod red. L. Lilli. Per. s angl. 3-e izd., ispr. i pererab (in Russian)]. Moscow. 2010; 672 s.
4. The branch standard “Clinico-economic studies. General provisions”. The order of the MoH of Russia from 27.05.2002 № 163 and OST 91500.14.0001-2002. [Otraslevoi standart «Kliniko-ekonomicheskie issledovaniya. Obshchie polozheniya». Prikaz Minzdrava Rossii ot 27.05.2002 № 163 i OST 91500.14.0001-2002 (in Russian)]. URL: http://www.healtheconomics.ru/2009-06-04-21-59-10/item/300-prikaz-minzdrava-rf-ot-27- 05-2002-163-ob-utverzhdenii-otraslevogo-standarta-kliniko-ekonomicheskie-issledovaniya- obshchie-polozheniya-vmeste-s-ost-91500-14-0001-2002. Accessed: 15.09.2016.
5. Ponomareva A. I., Gudkov G. V., Shevchenko N. P. i dr. Zdorov’e i obrazovanie v XXI Veke. 2009; 11 (12): 535 s.
6. Reshet’ko O. V., Lutsevich K. A. Vedomosti nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya. 2015; 4: 54-57.
7. Khalafyan A. A., Koshkarov A. A., Fabritskaya E. Yu. Fundamental’nye issledovaniya. 2016; 4: 323-327.
8. Chazova I. E., Oshchepkova E. V., Zhernakova Yu. V. Kardiologicheskii vestnik. 2015; 10 (1): 3-30.
9. Yagudina R. I., Kulikov A. Yu., Metelkin I. A. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2012; 5 (4): 3-8.
10. Edlin R., Round J., Hulme C. et al. Cost-effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists. Br. J. Clin. Pharmacol. 2010; 70 (3): 350-355. DOI: 10.1111/j.1365-2125.2010.03617.x.
11. Morrison V. L., Holmes E. A., Parveen S. Predictors of self-reported adherence to antihypertensive medicines: a multinational, cross-sectional survey. Value Health. 2015; 18 (2): 206-216. DOI: 10.1016/j.jval.2014.12.013.
12. Yevstigneev S. V., Titarenko A. F., Abakumova T. R., Alexandrova E. G. et al. Towards the rational use of medicines. Int J Risk Saf Med. 2015; 27 (1): 59-60. DOI: 10.3233/JRS-150690.
For citation:
Kaskaeva D.S., Petrova M.M., Zimnitskaya O.V. PHARMACOECONOMIC STUDY OF OLMESARTAN/LERCANIDIPINE AND OFENOPRIL/LERCANIDIPINE COMBINATIONS IN THE TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2016;9(4):3-8. (In Russ.) https://doi.org/10.17749/2070-4909.2016.9.4.003-008
Views: 910
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 